Is Quoin pharmaceuticals (Quoin) a good stock to buy?

Currently, the analyst consensus on Quoin Pharmaceuticals is a Strong Buy with an average price target of $13.25, a 624.0% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $8.00 price target.

Does Quoin pharmaceuticals have a global sales and distribution network?

Emerging specialty pharmaceutical company, Quoin Pharmaceuticals (Nasdaq: QNRX) recognized early on that the establishment of a global sales and distribution network for its products could be a crucial competitive advantage. So, how has Quoin’s management team approached this differently?

Is Quoin Pharmaceuticals building for future success?

Quoin Pharmaceuticals: Strategically Building For Future Success PCG DigitalJune 14, 2022 GMT "Rare diseases are only rare if you don’t live with one" "Rare diseases are only rare if you don’t live with one" As the rare disease drug development landscape continues to evolve, Quoin (Nasdaq:QNRX) is focused on staying ahead of its competitors.